SF tech start­up Atom­wise gets $45M for AI-pow­ered drug de­sign soft­ware

A Sil­i­con Val­ley soft­ware com­pa­ny that’s us­ing ar­ti­fi­cial in­tel­li­gence to take the guess work out of struc­ture-based drug de­sign is trot­ting out a siz­able Se­ries A round this morn­ing. The deal in­cludes in­vestors that run the gamut, from tech to bio­phar­ma to agro­chem­i­cals.

The com­pa­ny is called Atom­wise, and it’s haul­ing in $45 mil­lion in a round led by Mon­san­to Growth Ven­tures, tech in­vestors DCVC (Da­ta Col­lec­tive), and B Group Cap­i­tal – the VC fund found­ed by Face­book co-founder Ed­uar­do Saverin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER